These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 23018042)

  • 21. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
    Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
    Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.
    Ureña-Torres P; Bridges I; Christiano C; Cournoyer SH; Cooper K; Farouk M; Kopyt NP; Rodriguez M; Zehnder D; Covic A
    Nephrol Dial Transplant; 2013 May; 28(5):1241-54. PubMed ID: 23328710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.
    Messa P; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Wilkie M; Zani VJ; Molemans B; Carter D; Locatelli F
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):36-45. PubMed ID: 18178780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
    Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD
    Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
    JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Effectiveness of Alternative Treatment Approaches to Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis: An Observational Trial Emulation.
    Platt A; Wilson J; Hall R; Ephraim PL; Morton S; Shafi T; Weiner DE; Boulware LE; Pendergast J; Scialla JJ;
    Am J Kidney Dis; 2024 Jan; 83(1):58-70. PubMed ID: 37690631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level].
    Mercadal Orfila G; Blasco Mascaró I
    Farm Hosp; 2012; 36(1):11-5. PubMed ID: 21514862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cinacalcet plus vitamin D versus vitamin D alone for the treatment of secondary hyperparathyroidism in patients undergoing dialysis: a meta-analysis of randomized controlled trials.
    Xu J; Yang Y; Ma L; Fu P; Peng H
    Int Urol Nephrol; 2019 Nov; 51(11):2027-2036. PubMed ID: 31531805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Mealing S; Roome C; Snaith A; D'Souza R; Welch K; Stein K
    Health Technol Assess; 2007 May; 11(18):iii, xi-xiii, 1-167. PubMed ID: 17462168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
    Parfrey PS; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Dehmel B; Trotman ML; Modafferi DM; Goodman WG
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4834-44. PubMed ID: 24108314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
    Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
    J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy.
    Yokoyama K; Kurita N; Fukuma S; Akizawa T; Fukagawa M; Onishi Y; Kurokawa K; Fukuhara S
    Nephrol Dial Transplant; 2017 Mar; 32(3):534-541. PubMed ID: 26945054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Secondary hyperparathyroidism and anemia. Effects of a calcimimetic on the control of anemia in chronic hemodialysed patients. Pilot Study].
    Mpio I; Boumendjel N; Karaaslan H; Arkouche W; Lenz A; Cardozo C; Cardozo J; Pastural-Thaunat M; Fouque D; Silou J; Attaf D; Laville M
    Nephrol Ther; 2011 Jul; 7(4):229-36. PubMed ID: 21353659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.
    Raggi P; Chertow GM; Torres PU; Csiky B; Naso A; Nossuli K; Moustafa M; Goodman WG; Lopez N; Downey G; Dehmel B; Floege J;
    Nephrol Dial Transplant; 2011 Apr; 26(4):1327-39. PubMed ID: 21148030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of secondary hyperparathyroidism in renal insufficiency: role of calcitriol, sevelamer and cinacalcet].
    Bonny O; Burnier M
    Rev Med Suisse; 2008 Mar; 4(147):589-92, 594-5. PubMed ID: 18402017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mortality in dialysis patients with cinacalcet use: A large observational registry study.
    Friedl C; Reibnegger G; Kramar R; Zitt E; Pilz S; Mann JFE; Rosenkranz AR
    Eur J Intern Med; 2017 Jul; 42():89-95. PubMed ID: 28499709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.
    Fishbane S; Shapiro WB; Corry DB; Vicks SL; Roppolo M; Rappaport K; Ling X; Goodman WG; Turner S; Charytan C
    Clin J Am Soc Nephrol; 2008 Nov; 3(6):1718-25. PubMed ID: 18945995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of Cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis.
    Mei C; Chen N; Ding X; Yu X; Wang L; Qian J; Wang M; Jiang G; Li X; Hou F; Zuo L; Wang N; Liu H
    Hemodial Int; 2016 Oct; 20(4):589-600. PubMed ID: 26940692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
    Wilkie M; Pontoriero G; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Zani VJ; Carter D; Messa P
    Nephron Clin Pract; 2009; 112(1):c41-50. PubMed ID: 19365139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy.
    Eandi M; Pradelli L; Iannazzo S; Chiroli S; Pontoriero G
    Pharmacoeconomics; 2010; 28(11):1041-54. PubMed ID: 20936886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.